硫酸博莱霉素
硫酸博莱霉素结构式
|
常用名 | 硫酸博莱霉素 | 英文名 | Bleomycin sulfate |
|---|---|---|---|---|
| CAS号 | 9041-93-4 | 分子量 | 1512.62 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C55H85N17O25S4 | 熔点 | 197ºC (dec) | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS08 |
信号词 | Danger |
|
Ameliorative effect of mepenzolate bromide against pulmonary fibrosis.
J. Pharmacol. Exp. Ther. 350(1) , 79-88, (2014) Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis. A transforming growth factor (TGF)-β1-induced increase in myofibroblast number plays an important role in ... |
|
|
Transcription forms and remodels supercoiling domains unfolding large-scale chromatin structures.
Nat. Struct. Mol. Biol. 20(3) , 387-95, (2013) DNA supercoiling is an inherent consequence of twisting DNA and is critical for regulating gene expression and DNA replication. However, DNA supercoiling at a genomic scale in human cells is uncharacterized. To map supercoiling, we used biotinylated trimethyl... |
|
|
Latent transforming growth factor-β1 protects against bleomycin-induced lung injury in mice.
Am. J. Respir. Cell. Mol. Biol. 51(6) , 761-71, (2014) Transforming growth factor (TGF)-β1 is a potent mediator known to induce lung fibrosis. However, the role of latent TGF-β1 in lung inflammation and fibrosis is unclear. To investigate the role of circulating latent TGF-β1 in bleomycin-induced lung injury, lun... |
|
|
PET/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis.
J. Nucl. Med. 56(1) , 127-32, (2015) Idiopathic pulmonary fibrosis is characterized by a progressive and irreversible respiratory failure. Validated noninvasive methods able to assess disease activity are essential for prognostic purposes as well as for the evaluation of emerging antifibrotic tr... |
|
|
Upregulation of the Saccharomyces cerevisiae efflux pump Tpo1 rescues an Imp2 transcription factor-deficient mutant from bleomycin toxicity.
Environ. Mol. Mutagen. 55(6) , 518-24, (2014) Yeast mutants lacking the transcriptional co-activator Imp2 are hypersensitive to the anticancer drug bleomycin, although the gene targets involved in this process remain elusive. A search for multicopy suppressors that rescue the imp2Δ mutant from bleomycin ... |
|
|
[Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
Vopr. Onkol. 59(2) , 59-65, (2013) In a retrospective study during the primary mode MOPP to primary patients LH II/IVAB stages with a poor prognosis rate of CR, 5--and 10-year DFS, OS was 69%, 71% and 68%, 74% and 64%, ABVD--76%, 78%, 83% and 68%, BEACOPP-baseline--73%, 97%, 85% and 82%, respe... |
|
|
[Treatment of advanced Hodgkin lymphoma].
Dtsch. Med. Wochenschr. 138(23) , 1212-4, (2013)
|
|
|
Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
Anticancer Res. 33(9) , 3879-85, (2013) Hodgkin lymphoma (HL) is characterized by malignant Reed-Sternberg cells which express CD30. Current National Comprehensive Cancer Network guidelines for patients with advanced HL (stage III/IV disease) recommend adriamycin, bleomycin, vinblastine, and dacarb... |
|
|
Kaposi’s sarcoma in children: An open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin
Eur. J. Cancer 50(8) , 1472-81, (2014) Introduction Kaposi’s sarcoma (KS) is a common childhood cancer in places where HIV is endemic and access to antiretroviral therapy (ART) is delayed. Despite this there are no randomised trials to compare and assess chemotherapeutic regimens. |
|
|
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Ann. Hematol. 93(8) , 1297-304, (2014) The choice of a rituximab-based regimen and the prognostic significance of interim 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in primary mediastinal large B cell lymphoma (PMBCL) are debatable. We eva... |